ArticleJMIR medical informatics2025
Regulatory Insights From 27 Years of Artificial Intelligence/Machine Learning-Enabled Medical Device Recalls in the United States: Implications for Future Governance.
Article in JMIR medical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- AI-coded radiation therapy software requires unique quality assurance.Journal of applied clinical medical physics · 2026Article
- Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026Review
- Regulatory Approaches to Cybersecurity Risk Management for AI-Enabled Medical Device Software in Korea, the United States, and the European Union: Comparative Document Analysis.JMIR medical informatics · 2026Article
- The absence of full lifecycle risk management for AI-based medical devices in radiology.NPJ digital medicine · 2026Article
- Approval of AI-Based Medical Devices in China From 2020 to 2025: Retrospective Analysis.JMIR medical informatics · 2026Article
- From model failure to system harm: operationalizing a sociotechnical pathway for healthcare AI safety.Frontiers in artificial intelligence · 2026Article
- Artificial intelligence in membranous nephropathy: transforming clinical management toward precision medicine.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Artificial intelligence/machine learning (AI/ML) has revolutionized the health care industry, particularly in the development and use of medical devices. The US Food and Drug Administration (FDA) has authorized over 878 AI/ML-enabled medical devices, reflecting a growing trend in both quantity and application scope. Understanding the distinct challenges these devices present in terms of FDA regulation violations is crucial for effectively avoiding recalls. This is particularly pertinent for proactive measures regarding medical devices. Objective: This study explores the impact of AI/ML on medical device recalls, focusing on the distinct causes associated with AI/ML-enabled devices compared with other device types. Recall information associated with 510(k)-cleared devices was obtained from openFDA. Three recall cohorts were established: "All 510(k) devices recall," "software-related devices recall," and "AI/ML devices recall." Methods: Recall information for 510(k)-cleared devices was obtained from openFDA. AI/ML-enabled medical devices were identified based on FDA listings. Three cohorts were established: "All 510(k) devices recall," "software-related devices recall," and "AI/ML devices recall." Root cause analysis was conducted for each recall event. Results: The results indicate that while the top 5 recall root causes are relatively similar across the 3 control groups, the proportions vary, with AI/ML devices showing a higher impact for 87% of all recalls. Design and development-related factors play a significant role in recalls of AI/ML devices with root causes related to device design and software design accounting for 50% of recalls, emphasizing the importance of thorough planning, user feedback incorporation, and validation during the development process to reduce the probability of recalls. In addition, changes in software, including design changes and control changes, also contribute substantially to recalls in AI/ML devices. Conclusions: In conclusion, this study provides valuable insights into the unique challenges and considerations associated with AI/ML-enabled medical device recalls, offering guidance for manufacturers to enhance verification plans and mitigate risks in this rapidly evolving technological landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.